RT Journal Article
T1 Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
A1 Santonja, Ángela
A1 Sánchez-Muñoz, Alfonso
A1 Lluch, Ana
A1 Chica Parrado, María del  Rosario
A1 Albanell, J.
A1 Chacón, José Ignacio
A1 Antolín, Silvia
A1 Jerez-Aragonés, José Manuel
A1 De la Haba, Juan
A1 De Luque, Vanessa
A1 Fernández-De-Sousa, Cristina Elisabeth
A1 Vicioso-Recio, Luis Prudencio
A1 Plata-Fernández, Yéssica
A1 Ramírez-Tortosa, César
A1 Álvarez-Pérez, Martína
A1 Llácer, Casilda
A1 Zarcos-Pedrinaci, Irene
A1 Carrasco, Eva
A1 Caballero, Rosalía
A1 Martín, Miguel
A1 Alba-Conejo, Emilio
K1 Cáncer - Tratamiento
K1 Carcinogénesis
K1 Quimioterapia
AB Triple negative breast cancer (TNBC) is a heterogeneous disease with distinctmolecular subtypes that differentially respond to chemotherapy and targeted agents.The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypesby identifying any differences in response to neoadjuvant chemotherapy amongthem. We determined Lehmann subtypes by gene expression profiling in paraffinedpre-treatment tumor biopsies from 125 TNBC patients treated with neoadjuvantanthracyclines and/or taxanes +/- carboplatin. We explored the clinicopathologicalcharacteristics of Lehmann subtypes and their association with the pathologic completeresponse (pCR) to different treatments. The global pCR rate was 37%, and it wasunevenly distributed within Lehmann’s subtypes. Basal-like 1 (BL1) tumors exhibitedthe highest pCR to carboplatin containing regimens (80% vs 23%, p=0.027) and werethe most proliferative (Ki-67>50% of 88.2% vs. 63.7%, p=0.02). Luminal-androgenreceptor (LAR) patients achieved the lowest pCR to all treatments (14.3% vs 42.7%,p=0.045 when excluding mesenchymal stem-like (MSL) samples) and were the groupwith the lowest proliferation (Ki-67≤50% of 71% vs 27%, p=0.002). In our cohort,only tumors with LAR phenotype presented non-basal-like intrinsic subtypes (HER2-enriched and luminal A). TNBC patients present tumors with a high genetic diversityranging from highly proliferative tumors, likely responsive to platinum-based therapies,to a subset of chemoresistant tumors with low proliferation and luminal characteristics.
PB Impact Journals
YR 2018
FD 2018-05-29
LK https://hdl.handle.net/10630/31190
UL https://hdl.handle.net/10630/31190
LA eng
NO Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, Antolín S, Jerez JM, de la Haba J, de Luque V, Fernández-De Sousa CE, Vicioso L, Plata Y, Ramírez-Tortosa CL, Álvarez M, Llácer C, Zarcos-Pedrinaci I, Carrasco E, Caballero R, Martín M, Alba E. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018 May 29;9(41):26406-26416. doi: 10.18632/oncotarget.25413. PMID: 29899867; PMCID: PMC5995183.
NO Este articulo ha sido publicado en la revista Oncotarget.Esta versión tiene Licencia Creative Commons CC-BY
NO This work was supported by Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) fromInstituto de Salud Carlos III (ISCIII) (CB16/12/00241, CB16/12/00471, CB16/12/00481) and by research grantsfrom ISCIII (PI13/00730), Mutua Madrileña 2013 and Sociedad Española de Oncología Médica (SEOM) 2013.The authors acknowledge support through grant TIN2017- 88728-C2-1-R from MICINN-SPAIN. Angela Santonjahas a predoctoral grant PFIS-ISCIII (FI12/00489).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 25 feb 2026